sel-302
Gene therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 19, 2022 (NCT05778877)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Methylmalonyl-CoA mutase, mitochondrialSupplementation
supplementation - MMUT
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05778877 | Phase 1/Phase 2 (Phase 2) | Dec 19, 2022 | National Human Genome Research Institute (NHGRI), Selecta Biosciences, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Human Genome Research Institute (NHGRI) | Government | 1 | 0 | 1 | 2022 |
| Selecta Biosciences, Inc. | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1